LRG1在糖脂代谢疾病中的研究进展

doi:10.20047/j.issn1673-7210.2023.25.08

Abstract
Figure/Table
References (30)
Related Citation (15)

Download: PDF (465 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract Leucine-rich-α-2-glycoprotein 1 (LRG1) is one of the highly conserved member of the leucine-rich repeat protein family. Recent studies have found that LRG1 is a novel adipokine, which is closely related to glycolipid metabolism. In terms of glucose metabolism, LRG1 gene knockout can improve insulin resistance induced by high fat feeding, and LRG1 can inhibit insulin signaling and promote liver gluconeogenesis. In terms of lipid metabolism, LRG1 gene knockout can inhibit lipid synthesis and reduce serum triglyceride and cholesterol levels. In addition, the levels of LRG1 in obese people and obese mice are significantly higher, and the level of LRG1 is significantly correlated with a variety of diabetes complications, suggesting that LRG1 may be a risk factor for obesity and diabetes vascular complications. This article reviews the research progress of LRG1 in glycolipid metabolism and related diseases, in order to provide a new direction for the prediction and treatment of glycolipid metabolism related diseases.

Key words： Leucine-rich-α-2-glycoprotein 1 Insulin resistance Obesity Glycolipid metabolism Diabetic complications

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	ZHENG Shuyue XIA Yue JIA Jue DENG Xia WANG Dong

Cite this article:

ZHENG Shuyue XIA Yue JIA Jue DENG Xia WANG Dong. Research progress of LRG1 in glucolipid metabolic diseases[J]. 中国医药导报, 2023, 20(25): 47-50.

URL:

https://www.yiyaodaobao.com.cn/EN/10.20047/j.issn1673-7210.2023.25.08 OR https://www.yiyaodaobao.com.cn/EN/Y2023/V20/I25/47

[1] Zou Y，Xu Y，Chen X，et al. Research Progress on Leucine- Rich Alpha-2 Glycoprotein 1：A Review [J]. Front Pharmacol，2021，12：809225.
[2] De Rossi G，Da VLM，Greenwood J，et al. LRG1 as a novel the- rapeutic target in eye disease [J]. Eye （Lond），2022，36（2）：328-340.
[3] Camilli C，Hoeh AE，De Rossi G，et al. LRG1：an emerging player in disease pathogenesis [J]. J Biomed Sci，2022，29（1）：6.
[4] Kim CS，Brown AM，Grove TZ，et al. Designed leucine-rich repeat proteins bind two muramyl dipeptide ligands [J]. Protein Sci，2021，30（4）：804-817.
[5] Druhan LJ，Lance A，Li S，et al. Leucine Rich alpha-2 Glycoprotein： A Novel Neutrophil Granule Protein and Modulator of Myelopoiesis [J]. PLoS One，2017，12（1）：e170261.
[6] Wang X，Abraham S，McKenzie J，et al. LRG1 promotes angiogenesis by modulating endothelial TGF-beta signalling [J]. Nature，2013，499（7458）：306-311.
[7] He S，Ryu J，Liu J，et al. LRG1 is an adipokine that mediates obesity-induced hepatosteatosis and insulin resistance [J]. J Clin Invest，2021，131（24）.
[8] Trayhurn P. Adipokines：inflammation and the pleiotropic role of white adipose tissue [J]. Br J Nutr，2022，127（2）：161- 164.
[9] Mohammad H，Galal GS，Eladl MA，et al. Metformin suppresses LRG1 and TGFbeta1/ALK1-induced angiogenesis and protects against ultrastructural changes in rat diabetic nephropathy [J]. Biomed Pharmacother，2023，158：114128.
[10] Choi C，Barr W，Zaman S，et al. LRG1 is an adipokine that promotes insulin sensitivity and suppresses inflammation [J]. Elife，2022，11：e81559.
[11] Schmitz K，Turnwald EM，Kretschmer T，et al. Metformin Prevents Key Mechanisms of Obesity-Related Complications in Visceral White Adipose Tissue of Obese Pregnant Mice [J]. Nutrients，2022，14（11）：2288.
[12] Al-Mansoori L，Al-Jaber H，Prince MS，et al. Role of Inflammatory Cytokines，Growth Factors and Adipokines in Adipogenesis and Insulin Resistance [J]. Inflammation，2022，45（1）：31-44.
[13] Alhammad R，Abu-Farha M，Hammad MM，et al. Increased LRG1 Levels in Overweight and Obese Adolescents and Its Association with Obesity Markers，Including Leptin，Che- merin，and High Sensitivity C-Reactive Protein [J]. Int J Mol Sci，2022，23（15）：8564.
[14] Iqbal Z，Fachim HA，Gibson JM，et al. Changes in the Proteome Profile of People Achieving Remission of Type 2 Diabetes after Bariatric Surgery [J]. J Clin Med，2021，10（16）： 3659.
[15] Pek S，Cheng A，Lin MX，et al. Association of circulating proinflammatory marker，leucine-rich-alpha2-glycoprotein （LRG1），following metabolic/bariatric surgery [J]. Diabetes Metab Res Rev，2018，34（7）：e3029.
[16] Chen Y，Liu Z，Gong Y. Correlations of coronary artery disease degree with endothelial function and glucose meta- bolism in patients with type 2 diabetes mellitus complicated with coronary heart disease [J]. Minerva Med，2023，114（1）：127-129.
[17] Flores-Romero H，Hohorst L，John M，et al. BCL-2-family protein tBID can act as a BAX-like effector of apoptosis [J]. EMBO J，2022，41（2）：e108690.
[18] Feng J，Zhan J，Ma S. LRG1 promotes hypoxia-induced cardiomyocyte apoptosis and autophagy by regulating hypoxia-inducible factor-1alpha[J]. Bioengineered，2021，12（1）：8897-8907.
[19] Theofilis P，Oikonomou E，Tsioufis K，et al. Diabetes Mellitus and Heart Failure： Epidemiology，Pathophysiologic Mec-hanisms，and the Role of SGLT2 Inhibitors [J]. Life （Basel），2023，13（2）：497.
[20] Liu JJ，Pek S，Wang J，et al. Association of Plasma Leucine- Rich alpha-2 Glycoprotein 1，a Modulator of Transforming Growth Factor-beta Signaling Pathway，With Incident Heart Failure in Individuals With Type 2 Diabetes [J]. Diabetes Care，2021，44（2）：571-577.
[21] Tang L，Xu GT，Zhang JF. Inflammation in diabetic retin- opathy： possible roles in pathogenesis and potential implications for therapy [J]. Neural Regen Res，2023，18（5）：976- 982.
[22] Shye M，Hanna RM，Patel SS，et al. Worsening proteinuria and renal function after intravitreal vascular endothelial gro- wth factor blockade for diabetic proliferative retinopathy [J]. Clin Kidney J，2020，13（6）：969-980
[23] Chen C，Chen X，Huang H，et al. Elevated plasma and vitreous levels of leucine-rich-alpha2-glycoprotein are associated with diabetic retinopathy progression [J]. Acta Ophthalmol，2019，97（3）：260-264.
[24] Zhang X，Pek S，Tavintharan S，et al. Leucine-rich alpha-2-glycoprotein predicts proliferative diabetic retino- pathy in type 2 diabetes [J]. J Diabetes Complications，2019， 33（9）：651-656.
[25] Li W，Wang X，Cheng J，et al. Leucine-rich alpha-2-glycoprotein-1 promotes diabetic corneal epithelial wound healing and nerve regeneration via regulation of matrix metalloproteinases [J]. Exp Eye Res，2020，196：108060.
[26] Tong L，Adler SG. Diabetic Kidney Disease [J]. Clin J Am Soc Nephrol，2018，13（2）：335-338.
[27] Adler AI，Stevens RJ，Manley SE，et al. Development and progression of nephropathy in type 2 diabetes： the United Kingdom Prospective Diabetes Study （UKPDS 64）[J]. Kidney Int，2003，63（1）：225-232.
[28] Hong Q，Zhang L，Fu J，et al. LRG1 Promotes Diabetic Kidney Disease Progression by Enhancing TGF-beta-Induced Angiogenesis [J]. J Am Soc Nephrol，2019，30（4）：546-562.
[29] Hong Q，Cai H，Zhang L，et al. Modulation of transforming growth factor-beta-induced kidney fibrosis by leucine- rich α-2 glycoprotein-1 [J]. Kidney Int，2022，101（2）：299- 314.
[30] Liu JJ，Liu S，Wang J，et al. Urine Leucine-Rich alpha-2 Glycoprotein 1 （LRG1） Predicts the Risk of Progression to End-Stage Kidney Disease in Patients With Type 2 Diabetes [J]. Diabetes Care，2023，46（2）：408-415.